Balyasny Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Balyasny Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-250,000	Closed	-$39.1M	–	2234
2020 Q4	$39.1M	Buy	250,000 +80,000	+47%	+$10.3M	0.22%	112
2020 Q3	$19.5M	Buy	170,000 +120,000	+240%	+$12.9M	0.14%	194
2020 Q2	$5.61M	Hold	50,000	–	–	0.05%	489
2020 Q1	$4.49M	Sell	50,000 -200,000	-80%	-$19.6M	0.05%	432
2019 Q4	$27M	Buy	+250,000	New	+$26.7M	0.16%	193
2019 Q1	–	Sell	-99,000	Closed	-$9.64M	–	1763
2018 Q4	$9.64M	Sell	99,000 -72,000	-42%	-$8.51M	0.07%	365
2018 Q3	$20.9M	Sell	171,000 -95,200	-36%	-$11.9M	0.09%	290
2018 Q2	$33M	Sell	266,200 -390,300	-59%	-$45.6M	0.15%	186
2018 Q1	$73.2M	Sell	656,500 -142,300	-18%	-$17M	0.31%	63
2017 Q4	$95.5M	Buy	+798,800	New	+$97.3M	0.3%	69
2017 Q3	–	Sell	-67,500	Closed	-$8.21M	–	2168
2017 Q2	$8.21M	Sell	67,500 -42,500	-39%	-$4.95M	0.03%	592
2017 Q1	$13.3M	Sell	110,000 -116,500	-51%	-$15M	0.06%	397
2016 Q4	$27.7M	Buy	+226,500	New	+$27.7M	0.15%	191
2016 Q3	–	Sell	-80,000	Closed	-$9.34M	–	1361
2016 Q2	$9.34M	Buy	+80,000	New	+$11.4M	0.06%	369
2015 Q2	–	Sell	-50,000	Closed	-$8.66M	–	1400
2015 Q1	$8.66M	Buy	+50,000	New	+$9.05M	0.07%	372

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Balyasny Asset Management's ALXN Position: Q3 2021 in Review

Balyasny Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 771,620 shares — an estimated $142M sold.

Balyasny Asset Management first reported a position in ALXN in Q2 2014 and held it in 26 quarters. The position peaked at $147M in Q4 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Balyasny Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Balyasny Asset Management sold 771,620 Alexion Pharmaceuticals shares in Q3 2021, an estimated $142M.
Balyasny Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 26 quarters.
Balyasny Asset Management's Alexion Pharmaceuticals position peaked at $147M in Q4 2017.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.